Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice.
Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain. For this reason, the team of researchers led by Christophe Bernard at Inserm Unit 1106, “Institute of Systems Neuroscience” (INS), with the help of scientists at the École des Mines de Saint-Étienne and Linköping University (Sweden) have developed an organic electronic micropump which, when combined with an anticonvulsant drug, enables localised inhibition of epileptic seizure in brain tissue in vitro. This research is published in the journal Advanced Materials.
Drugs constitute the most widely used approach for treating brain disorders. However, many promising drugs failed during clinical testing for several reasons:
- they are diluted in potentially toxic solutions,
- they may themselves be toxic when they reach organs to which they were not initially directed,
- the blood-brain barrier, which separates the brain from the blood circulation, prevents most drugs from reaching their targets in the brain,
- drugs that succeed in penetrating the brain will act in a non-specific manner, i.e. on healthy regions of the brain, altering their functions.
Epilepsy is a typical example of a condition for which many drugs could not be commercialised because of their harmful effects, when they might have been effective for treating patients resistant to conventional treatments .
During an epileptic seizure, the nerve cells in a specific area of the brain are suddenly activated in an excessive manner. How can this phenomenon be controlled without affecting healthy brain regions? To answer this question, Christophe Bernard’s team, in collaboration with a team led by George Malliaras at the Georges Charpak-Provence Campus of the École des Mines of Saint-Étienne and Swedish scientists led by Magnus Berggren from Linköping University, have developed a biocompatible micropump that makes it possible to deliver therapeutic substances directly to the relevant areas of the brain.
The micropump (20 times thinner than a hair) is composed of a membrane known as “cation exchange,” i.e., it has negative ions attached to its surface. It thus attracts small positively charged molecules, whether these are ions or drugs. When an electrical current is applied to it, the flow of electrons generated projects the molecules of interest toward the target area.
The Latest on: Drug delivery system
via Google News
The Latest on: Drug delivery system
- Global Topical Drug Delivery System Manufacturers, to study the Capacity, Value, Share and Development Plans in Future.on May 12, 2020 at 9:23 pm
Topical Drug Delivery S Glaxosmithkline, Johnson & Johnson, Novartis, Galderma S.A. Impact of COVID-19 Blepharopl ...
- Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeuticson May 12, 2020 at 5:00 am
INTRODUCTION According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), ...
- Drug Delivery Devices Market Assessment 2015-2030 (COVID-19 Adjusted)on May 11, 2020 at 1:33 am
The "Drug Delivery Devices Global Market Report 2020-30: Covid 19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The global drug delivery devices market is ...
- Global Drug Delivery Devices Market 2020-2030: COVID-19 Implications and Growth - ResearchAndMarkets.comon May 7, 2020 at 8:08 am
The global drug delivery devices market is expected to grow from $1.4 billion in 2019 to about $1.6 billion in 2020, as there is a marginal increase in demand due to the use of such devices in the ...
- Global Buccal Drug Delivery Systems Market 2020 Industry Size, Segments, Share, Key Players and Growth Factor Analysis by 2026on May 7, 2020 at 4:15 am
MarketsandResearch.biz has recently published a research report titled, Global Buccal Drug Delivery Systems Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 which offers a ...
- Electronic Drug Delivery Systems Market Size Worth $12.1 Bn By 2027 | Anticipating a CAGR of 8.9%on May 7, 2020 at 2:06 am
The global Electronic Drug Delivery Systems Market is projected to reach more than US$ 12.1 Billion By 2027 with a CAGR of 8.9% during the forecast period, As per the research done by Acumen Research ...
- "Corkscrew” microrobots skewer cancer cells for targeted drug deliveryon May 6, 2020 at 8:39 pm
In the not too distant future, tiny robots could be delivering drugs inside our bodies, but there are still a few hurdles to clear before we realize that scenario. Now researchers have developed ...
- The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019on May 6, 2020 at 7:55 pm
Reportlinker.com announces the release of the report "Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and ...
- Global Non-Invasive Drug Delivery Devices Market (2019 to 2025) - Analysis and Forecast - ResearchAndMarkets.comon May 5, 2020 at 1:44 am
Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering. According to this market intelligence report, the global non-invasive drug delivery devices market was ...
- New Study Shows Promising Compounded Drug-Delivery Option for Patients with Oral Inflammatory Conditionon May 4, 2020 at 11:33 am
Research reveals a compounded steroid solution with MucoLox was clinically well tolerated and effective for patients with oral inflammatory condition.
via Bing News